Testing changed immune cells in people whose glioblastoma has come back
Original title: Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to find a safe dose.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a new kind of immune cell in people whose glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary has returned.
Who this trial is for. This trial is for people with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary that has come back. It tests natural killer cells, a type of immune cell. The cells come from cord blood. Two genes in them, TGF-betaR2 and NR3C1, have been removed. The idea is that this change may help the cells control the disease.
Where it stands. There are no results yet. The team is trying to find the best dose. They are also watching for side effects and for any possible benefit. This trial has not reported results.
What this means, and what it doesn't
What it could mean: This is one more idea being tested for glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary that has come back. It is not care your own doctor can give you today. If this sounds like your situation, you can ask your care team about it. They can tell you if it makes sense to look into.
What it doesn't mean: This does not mean the treatment works. A trial is a test, not a proven treatment. Joining a trial is not a promise that you will be helped. Some people are not helped at all, and side effects are still being learned. This is not a cure.
Source: ClinicalTrials.gov, July 30, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.